Profile data is unavailable for this security.
About the company
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
- Revenue in USD (TTM)0.00
- Net income in USD-381.44m
- Incorporated2017
- Employees218.00
- LocationNuvalent IncOne Broadway, 14th FloorCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 357-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.nuvalent.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics Inc | 209.22m | 45.91m | 5.09bn | 128.00 | 129.07 | 7.88 | 107.59 | 24.35 | 0.6313 | 0.6313 | 3.26 | 10.34 | 0.3205 | -- | 52.34 | 1,660,452.00 | 7.03 | -7.11 | 7.55 | -7.93 | -- | -- | 21.94 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.24bn | 362.00 | -- | 5.31 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Alkermes Plc | 1.52bn | 338.06m | 5.48bn | 1.80k | 16.43 | 3.16 | 14.87 | 3.60 | 2.02 | 2.02 | 9.06 | 10.50 | 0.6784 | 1.11 | 4.20 | 845,187.80 | 15.08 | 6.99 | 19.01 | 9.14 | 86.04 | 83.31 | 22.22 | 10.68 | 3.27 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
| Immunitybio Inc | 82.56m | -348.62m | 5.86bn | 673.00 | -- | -- | -- | 70.93 | -0.4079 | -0.4079 | 0.0965 | -0.5323 | 0.1869 | 0.0857 | 4.56 | 121,404.40 | -78.93 | -109.27 | -91.33 | -251.12 | 90.40 | -- | -422.38 | -11,599.51 | 5.65 | -2.20 | 2.77 | -- | 2,270.58 | 46.27 | 29.09 | -- | 9.95 | -- |
| Cogent Biosciences Inc | 0.00 | -214.77m | 6.40bn | 205.00 | -- | 26.26 | -- | -- | -1.77 | -1.77 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -72.69 | -57.20 | -84.75 | -63.62 | -- | -- | -- | -9,345.59 | -- | -- | 0.1276 | -- | -- | -- | -30.01 | -- | 76.98 | -- |
| Kymera Therapeutics Inc | 43.73m | -295.12m | 6.57bn | 225.00 | -- | 6.24 | -- | 150.23 | -3.59 | -3.59 | 0.5332 | 13.19 | 0.0409 | -- | 66.41 | 232,627.70 | -27.62 | -23.82 | -29.53 | -27.88 | -- | -- | -674.81 | -240.35 | -- | -- | 0.0039 | -- | -40.11 | 74.20 | -52.32 | -- | 89.02 | -- |
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.57bn | 25.00 | -- | 38.25 | -- | -- | -1.55 | -1.55 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| ICON PLC | 8.10bn | 599.48m | 7.10bn | 39.80k | 12.57 | 0.7608 | 7.19 | 0.8764 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.63bn | 414.00 | -- | 2.43 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.79bn | 218.00 | -- | 8.62 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 7.94bn | 18.60k | -- | 2.33 | 22.85 | 1.97 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 8.10bn | 498.00 | -- | -- | -- | 92.89 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.69bn | 116.00 | -- | 19.55 | -- | 1,165.07 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.94bn | 711.00 | 41.42 | 15.43 | 34.55 | 8.19 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 9.24bn | 2.40k | -- | 18.19 | -- | 8.36 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 9.38bn | 3.10k | 118.08 | 4.65 | 51.03 | 7.71 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
Data as of Feb 13 2026. Currency figures normalised to Nuvalent Inc's reporting currency: US Dollar USD
50.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 9.76m | 14.50% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 5.27m | 7.83% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.82m | 7.16% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.13m | 4.65% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 2.22m | 3.30% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 2.14m | 3.18% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 1.76m | 2.62% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.57m | 2.34% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 1.56m | 2.32% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2025 | 1.51m | 2.25% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
